Skip to content

Narrow Band Imaging Versus White Light for the Detection and Miss of Sessile Serrated Lesion

Narrow Band Imaging Versus White Light for the Detection and Miss of Sessile Serrated Lesions:a Multicenter,Random,Back-to-back Trial

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05684328
Enrollment
840
Registered
2023-01-13
Start date
2023-02-01
Completion date
2024-05-28
Last updated
2024-03-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Sessile Serrated Lesion

Keywords

Sessile Serrated Lesions Miss Rate, Sessile Serrated Lesions Detection Rate, Narrow Band Imaging, Colonoscopy

Brief summary

Narrow band imaging(NBI) could improve the detection of colorectal lesions, previous investigations demonstrated its potential in detecting not only colorectal adenoma but non-adenomatous polyps, including sessile serrated lesions. But no randomized controlled trials with NBI versus white light imaging(WLI) have been conducted to give a definitive conclusion with statistically significant differences. Therefore, we performed a multicenter, prospective, back to back, randomized controlled trial to compare sessile serrated lesions detection and miss rate of withdraw by NBI and WLI in colonoscopy.

Interventions

PROCEDUREWLI Then NBI Withdrawal

Patients in WLI then NBI withdrawal group will first be carefully inspected by white light imaging(WLI), each polyp found should be removed. According to the ESGE guideline of colorectal polypectomy, the lesions which size between 4-9mm should by removed by cold snare. Cold biopsy forceps could be utilized considering the difficulty in resection of flat and diminutive polyps(size ≤ 3mm). Then change to narrow band imaging(NBI) for the second withdraw to detect the lesions which found in second time but not the first.

PROCEDURENBI Then WLI Withdrawal

Patients in NBI then WLI withdrawal group will first be carefully inspected by narrow band imaging(NBI), each polyp found should be removed. According to the ESGE guideline of colorectal polypectomy, the lesions which size between 4-9mm should by removed by cold snare. Cold biopsy forceps could be utilized considering the difficulty in resection of flat and diminutive polyps(size ≤ 3mm). Then change to white light imaging(WLI) for the second withdraw to detect the lesions which found in second time but not the first.

Sponsors

The First Affiliated Hospital of Dalian Medical University
CollaboratorOTHER
The Second Hospital of Hebei Medical University
CollaboratorOTHER
Yantaishan Hospital
CollaboratorUNKNOWN
The Second Affiliated Hospital of Guangzhou University of Chinese Medicine
CollaboratorUNKNOWN
900 Hospital of Joint Logistics Support Force of PLA
CollaboratorOTHER
Heilongjiang provincial hospital
CollaboratorUNKNOWN
Ankang Central Hospital
CollaboratorOTHER
Nongken Jiansanjiang People Hospital of Heilongjiang Province
CollaboratorUNKNOWN
Huadong Hospital
CollaboratorOTHER
The Second Affiliated Hospital of Baotou Medical College
CollaboratorOTHER
Qilu Hospital, Shandong University
CollaboratorUNKNOWN
Shandong First Medical University
CollaboratorOTHER
Air Force Military Medical University, China
CollaboratorOTHER
Tengzhou Central People's Hospital
CollaboratorOTHER_GOV
Chongqing General Hospital
CollaboratorOTHER
Haikou People's Hospital
CollaboratorOTHER
Changhai Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
DIAGNOSTIC
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
45 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* Patients whose age are between 45-85 * Patients who have indications for screening * Patients who have signed inform consent form.

Exclusion criteria

* Patients who have undergone colonic resection * Patients with alarming signs and symptoms of colorectal cancer: hematochezia, melena, anemia, weight loss, abdominal mass, positive digital rectal examination * Patients with highly suspected or confirmed colorectal cancers by radiographic and laboratory tests * Patients with abnormal blood coagulation or taking antiplatelets or anticoagulants within 7 days before colonoscopy * Patients with inflammatory bowel diseases * Patients with hereditary colorectal cancer syndrome (including familial adenomatous polyposis). * Patients with pregnancy, severe chronic cardiopulmonary and renal disease. * Patients with therapeutic colonoscopy for existing lesions * Patients with failed cecal intubation * Patients with poor bowel preparation quality that necessitated a second bowel preparation * Patients refusing to participate or to provide informed consent

Design outcomes

Primary

MeasureTime frameDescription
sessile serrated lesions miss rate(SSLMR)60 minutesSessile serrated lesions(SSLs) detected in the second-pass examination were defined as missed SSLs; the sessile serrated lesions miss rate(SSLMR) was defined as follows: number of SSLs detected in the second-pass examination/total number of SSLs detected in both two pass.

Secondary

MeasureTime frameDescription
sessile serrated lesions detection rate(SSLDR)60 minutesSessile serrated lesions detection rate(SSLDR) is the number of patients with at least one sessile serrated lesion detected by narrow band imaging or white light imaging, divided by the total number of patients.
adenoma miss rate(AMR)60 minutesAdenomas detected in the second-pass examination were defined as missed adenomas; the adenoma miss rate(AMR) was defined as follows: number of adenomas detected in the second-pass examination/total number of adenomas detected in the two pass.
adenoma detection rate(ADR)60 minutesAdenoma detection rate(ADR) is the number of patients with at least one adenoma detected by narrow band imaging or white light imaging, divided by the total number of patients.

Countries

China

Contacts

Primary ContactZhaoshen Li, MD
li.zhaoshen@hotmail.com86-021-31161365
Backup ContactYu Bai, MD
baiyu1998@hotmail.com86-021-31161335

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026